Influenza
Australia's healthcare system is reeling under the pressure of a historic flu outbreak, with over 410,000 laboratory-confirmed cases reported in 2025. The Royal Australian College of General Practitioners (RACGP) has revealed that flu incidence has surged to 1,525 cases per 100,000 people, a nearly 11
Influenza
Research from the Vrije Universiteit Brussel (VUB) in Brussels, Belgium, has provided new data on the detachment dynamics of Influenza A virus particles from reconstructed cell surfaces. The study, published in the journal Nano Letters, examined the biochemical parameters that regulate the residence time of virions at the cell surface.
Influenza
Researchers have developed bioluminescent reporter influenza A viruses that can be used to track viral infections in real-time, offering new possibilities for studying and combating the virus. This innovative approach has been welcomed by the scientific community as a potential game-changer in the fight against influenza A viruses. Key Takeaways:
Influenza
Researchers at the National Cancer Institute (NCI) have made a significant discovery in understanding the mechanisms behind influenza A virus infection. According to a recent study published in bioRxiv, interferon-induced transmembrane (IFITM) proteins, specifically IFITM1 and IFITM3, work together to restrict virus entry in endolysosomes, providing critical antiviral protection against
Influenza viruses
Fresh data on RNA Viruses - Influenza A Virus reveals a significant correlation between age and increased severity of influenza infection. Research from China Agricultural University found that Apolipoprotein D (ApoD) plays a crucial role in mediating the increased vulnerability to influenza virus infection in older individuals. The study highlights
Influenza vaccines
The largest study of its kind, FLUNITY-HD, has demonstrated that Sanofi's high-dose influenza vaccine, Efluelda/Fluzone High-Dose, provides superior protection for older adults against hospitalization compared to standard-dose vaccines. The study, published in The Lancet, involved nearly half a million participants across several seasons and two geographic areas,
Influenza
A free flu vaccination program is underway for children in Wolverhampton, with the aim of protecting them and their family members from the flu virus. The vaccination is provided by healthcare professionals from Vaccination UK and is available for all children from Reception to Year 11. For children who may
COVID-19
As Americans head into fall vaccine season, concerns about the Centers for Disease Control and Prevention's (CDC) leadership and guidance are adding to the confusion. Despite the challenges, it's essential to follow the medical community's recommendations to safeguard public health. This guide provides a
Fluzone (Vaccine)
The largest study of its kind, FLUNITY-HD, has demonstrated that Sanofi's high-dose influenza vaccine, Efluelda/Fluzone High-Dose, provides superior protection for older adults against hospitalization compared to standard-dose vaccines. The study, published in The Lancet, involved nearly half a million participants across several seasons and two geographic areas,
Health care industry
Sanofi has announced new results from the FLUNITY-HD study, confirming that its high-dose influenza vaccine, Efluelda, offers significantly greater protection against hospitalisations in adults aged 65 and older. The study, published in The Lancet, included 466,320 participants across Denmark and Spain, making it the largest influenza vaccine effectiveness trial
Influenza vaccines
Sanofi has announced new results from the FLUNITY-HD study, confirming that its high-dose influenza vaccine, Efluelda, offers significantly greater protection against hospitalisations in adults aged 65 and older. The study, published in The Lancet, included 466,320 participants across Denmark and Spain, making it the largest influenza vaccine effectiveness trial
COVID-19
A new study published in PLOS Medicine has revealed that individuals with non-severe acute respiratory illness caused by SARS-CoV-2 experienced only modestly greater risk of post-acute sequelae (PAS) in comparison to those whose illness was caused by influenza. However, COVID-19 cases hospitalized for their initial illness experienced greater risk of
